skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Decline in Tested and Self-Reported Cognitive Functioning After Prophylactic Cranial Irradiation for Lung Cancer: Pooled Secondary Analysis of Radiation Therapy Oncology Group Randomized Trials 0212 and 0214

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [3];  [4];  [5];  [6];  [7];  [8];  [9];  [10]
  1. Central Dupage Hospital Cancer Center, Warrenville, Illinois (United States)
  2. Radiation Therapy Oncology Group Statistical Center, Philadelphia, Pennsylvania (United States)
  3. Nell Hodgson Woodfull School of Nursing, Emory University, Atlanta, Georgia (United States)
  4. University of Texas MD Anderson Cancer Center, Houston, Texas (United States)
  5. Medical College of Wisconsin, Milwaukee, Wisconsin (United States)
  6. University of Miami School of Medicine, Miami, Florida (United States)
  7. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania (United States)
  8. Princess Margaret Hospital, Toronto, ON (Canada)
  9. University of Texas Southwestern Moncreif Cancer Center, Fort Worth, Texas (United States)
  10. Henry Ford Health System, Detroit, Michigan (United States)

Purpose: To assess the impact of prophylactic cranial irradiation (PCI) on self-reported cognitive functioning (SRCF), a functional scale on the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). Methods and Materials: Radiation Therapy Oncology Group (RTOG) protocol 0214 randomized patients with locally advanced non-small cell lung cancer to PCI or observation; RTOG 0212 randomized patients with limited-disease small cell lung cancer to high- or standard-dose PCI. In both trials, Hopkins Verbal Learning Test (HVLT)-Recall and -Delayed Recall and SRCF were assessed at baseline (after locoregional therapy but before PCI or observation) and at 6 and 12 months. Patients developing brain relapse before follow-up evaluation were excluded. Decline was defined using the reliable change index method and correlated with receipt of PCI versus observation using logistic regression modeling. Fisher's exact test correlated decline in SRCF with HVLT decline. Results: Of the eligible patients pooled from RTOG 0212 and RTOG 0214, 410 (93%) receiving PCI and 173 (96%) undergoing observation completed baseline HVLT or EORTC QLQ-C30 testing and were included in this analysis. Prophylactic cranial irradiation was associated with a higher risk of decline in SRCF at 6 months (odds ratio 3.60, 95% confidence interval 2.34-6.37, P<.0001) and 12 months (odds ratio 3.44, 95% confidence interval 1.84-6.44, P<.0001). Decline on HVLT-Recall at 6 and 12 months was also associated with PCI (P=.002 and P=.002, respectively) but was not closely correlated with decline in SRCF at the same time points (P=.05 and P=.86, respectively). Conclusions: In lung cancer patients who do not develop brain relapse, PCI is associated with decline in HVLT-tested and self-reported cognitive functioning. Decline in HVLT and decline in SRCF are not closely correlated, suggesting that they may represent distinct elements of the cognitive spectrum.

OSTI ID:
22224524
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 86, Issue 4; Other Information: Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Prospective Study of Hippocampal-Sparing Prophylactic Cranial Irradiation in Limited-Stage Small Cell Lung Cancer
Journal Article · Sat Jul 01 00:00:00 EDT 2017 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22224524

Neurochemical Evidence of Potential Neurotoxicity After Prophylactic Cranial Irradiation
Journal Article · Tue Jul 01 00:00:00 EDT 2014 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22224524

Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results
Journal Article · Mon May 01 00:00:00 EDT 2017 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22224524